Coinfection

Coverage of IDWeek 2014

HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.

Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.

Full listing of coverage by topic

IDWeek 2014 website

10/17/14

alt

HCV Sexual Transmission: HIV Negative May Be at Risk, More Awareness and Testing Needed

Hepatitis C virus (HCV) is known to be sexually transmitted among HIV positive men who have sex with men, but HIV negative men may be at risk as well, according to recent reports. Other recent studies have looked at awareness of HCV sexual transmission and screening practices, suggesting that improvement is needed in both areas.

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

AIDS 2014 website

7/25/14

alt

Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

alt

Read more:

AIDS 2014: HIV/HCV Coinfected Have High Cure Rates with Interferon-free Hep C Combos

Two studies presented at the 20thInternational AIDS Conference this week in Melbourne showed that all-oral regimens of direct-acting antiviral agents for hepatitis C are safe and effective for HIV positive people. Both regimens demonstrated sustained virological response rates similar to those seen in people with HCV alone.

-- Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

-- AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

alt

Read more:

Coverage of the Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.

Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.

Full listing of coverage by topic

ICAAC 2014 website

9/8/14

alt

AIDS 2014: AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people coinfected with HIV and genotype 1 hepatitis C in the TURQUOISE-I study, according to a late-breaking report at the 20th International AIDS Conference (AIDS 2014) this week in Melbourne, Australia.

alt

Read more:

ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks led to sustained virological response in 94% of HIV positive people with mostly genotype 1a hepatitis C coinfection in the TURQUOISE-I study, according to data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more:

AIDS 2014: Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained virological response in 84% to 89% of HIV positive chronic hepatitis C patients with HCV genotypes 1, 2, 3, or 4, according to results from the PHOTON-2 study presented at the 20th International AIDS Conference in Melbourne, Australia. Cure rates were lower, however, for genotype 1a patients with liver cirrhosis.

alt

Read more: